Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: people (1000), residents (55)

Nivolumab 240mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Nivolumab_240mg

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The tr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Fulvestrant-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Fulvestrant-Ribociclib Regimen • Breast Cancer – Fulvestrant-Ribociclib Indication • Fulvestrant and ribociclib is indicated for oestrogen receptor-positive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Ribociclib.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

VenetoclaxLow

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (l
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

Nivolumab

Description: Chemotherapy Protocol GASTRIC CANCER Nivolumab Regimen • Gastric Cancer – Nivolumab Indication • The treatment of advanced gastric or gastro
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Nivolumab.pdf

Handling concerns and complaints policy

Description: Handling Complaints Policy, Version 13.0 Trust reference PET003 Version number 13.0 Description Policy to explain how University Hospital Southampton
Url: /Media/UHS-website-2019/Docs/Policies/Handling-concerns-and-complaints-policy.pdf

UHS Green Plan 2025-2028

Description: Green Plan 2025 - 2028 Approved November 2025 Contents 1 Executive Summary 2 Introduction and Context 3 Organisational Vision 4 Review of
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Sustainability-and-Green-Plan/UHS-Green-Plan-2025-2028.pdf

161 to 170 of 185

Previous … 15 16 17 18 19 Next